These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 29512868)

  • 1. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
    Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
    Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
    Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
    Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
    Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
    Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
    Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
    Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation.
    Brakemeier S; Pfau A; Zukunft B; Budde K; Nickel P
    Pharmacol Res; 2018 Aug; 134():61-67. PubMed ID: 29890253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comprehensive Evaluation of Risk Factors for Pneumocystis jirovecii Pneumonia in Adult Solid Organ Transplant Recipients: A Systematic Review and Meta-analysis.
    Permpalung N; Kittipibul V; Mekraksakit P; Rattanawong P; Nematollahi S; Zhang SX; Steinke SM
    Transplantation; 2021 Oct; 105(10):2291-2306. PubMed ID: 33323766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
    Tu GW; Ju MJ; Xu M; Rong RM; He YZ; Xue ZG; Zhu TY; Luo Z
    Nephrology (Carlton); 2013 Nov; 18(11):736-42. PubMed ID: 24571744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
    Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
    Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and outcomes of Pneumocystis pneumonia in solid organ transplant recipients: Impact of posttransplant lymphoproliferative disorder.
    Yetmar ZA; Duffy D; Smith BH; Vikram HR; Brumble L; Limper AH; Beam E
    Clin Transplant; 2023 Sep; 37(9):e15021. PubMed ID: 37195184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
    Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
    Avino LJ; Naylor SM; Roecker AM
    Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
    Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients.
    Ricciardi A; Gentilotti E; Coppola L; Maffongelli G; Cerva C; Malagnino V; Mari A; Di Veroli A; Berrilli F; Apice F; Toschi N; Di Cave D; Parisi SG; Andreoni M; Sarmati L
    PLoS One; 2017; 12(5):e0176881. PubMed ID: 28505159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of Pneumocystis jirovecii prophylaxis use among pediatric solid organ transplant providers.
    Paulsen G; Michaels MG; Danziger-Isakov L; Dipchand AI; Green M; McCulloch M
    Pediatr Transplant; 2020 Feb; 24(1):e13609. PubMed ID: 31713958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
    McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfonamide desensitization in solid organ transplant recipients: A protocol-driven approach during the index transplant hospitalization.
    Pryor JB; Olyaei AJ; Kirsch D; Strasfeld L
    Transpl Infect Dis; 2019 Dec; 21(6):e13191. PubMed ID: 31596538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk factor analysis and treatment experience in pneumocystis jirovecii pneumonia after kidney transplantation.
    Yang P; Zhu X; Liang W; Cai R
    Mycoses; 2021 May; 64(5):495-502. PubMed ID: 33368732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Risk Factors for Pneumocystis Jirovecii Pneumonia during Immunosuppressive Treatment in Patients with Ulcerative Colitis: A Retrospective Study.
    Kojima K; Sato T; Uchino M; Yokoyama Y; Takagawa T; Ohda Y; Hida N; Watanabe K; Hori K; Miwa H; Ikeuchi H; Nakamura S; Shimizu M
    J Gastrointestin Liver Dis; 2020 Jun; 29(2):167-173. PubMed ID: 32530983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
    Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
    Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.